Braslyn Ltd.
CIK 1642355 · last filed 2024-01-25
"Disclosed insider exposure" sums this person's most-recently-reported share counts across each company they're an insider in, multiplied by the current underlying price. It is not net worth — it misses retail holdings, private investments, real estate, index funds, and any company where the person isn't an SEC-reporting insider. For informational purposes only.
Charts
Trading activity, where the exposure sits, and each trade against the stock price.
MRTX price and trades
Daily close with each Form 4 filing on this company marked: green = open-market buy, red = open-market sale, purple = grants, exercises, gifts and other non-market transactions. Marker size scales with the dollar value.
Shares held
Shares owned after each reported transaction on this company (direct holdings as reported).
Open-market buying and selling
by monthDollar value of open-market purchases (code P, up) and sales (code S, down) across all companies, by filing month. Grants, exercises and gifts are excluded.
Exposure by company
latestMost recently reported shares × current price. Faded bars (*) have had no filing in 3 years, so the person may no longer hold them. Click a bar to chart that company.
Filer Profile
LEWIS DRIVE N7776
NEW PROVIDENCE, C5 00000
Holdings By Company
| Symbol | Role | Shares | Price | Disclosed Exposure | Lifetime OM Net | Filings | Latest Filed |
|---|---|---|---|---|---|---|---|
| Mirati Therapeutics, Inc. (MRTX) Delisted | 10%+ Owner | 3,135,557 | $58.70 | $184.06M | -$269.37M | 19 | 2021-03-10 |
| INSG | 10%+ Owner | 761,483 | $4.15 | $3.16M | -$36.81M | 1 | 2020-12-16 |
| Pandion Therapeutics, Inc. (PAND) Delisted | 10%+ Owner | 1,408,913 | $60.05 | $84.61M | $78.00M | 1 | 2020-07-21 |
Recent Filings · Page 2 of 3
22 filings| Filed | Symbol | Action | Net Shares | Net $ | Link |
|---|---|---|---|---|---|
| 2017-01-25 | Mirati Therapeutics, Inc. (MRTX) Delisted | Buy (P) | +77,533 | $414.6K | EDGAR |
| 2017-01-20 | Mirati Therapeutics, Inc. (MRTX) Delisted | Buy (P) | +61,158 | $334.0K | EDGAR |
| 2017-01-17 | Mirati Therapeutics, Inc. (MRTX) Delisted | Buy (P) | +119,887 | $658.9K | EDGAR |
| 2017-01-10 | Mirati Therapeutics, Inc. (MRTX) Delisted | Buy (P) | +581,870 | $3.26M | EDGAR |
| 2016-06-08 | Mirati Therapeutics, Inc. (MRTX) Delisted | Buy (P) | +376,902 | $3.75M | EDGAR |
| 2016-05-09 | Mirati Therapeutics, Inc. (MRTX) Delisted | Buy (P) | +65,782 | $1.20M | EDGAR |
| 2016-03-31 | Mirati Therapeutics, Inc. (MRTX) Delisted | Buy (P) | +3,400 | $64.9K | EDGAR |
| 2016-03-28 | Mirati Therapeutics, Inc. (MRTX) Delisted | Buy (P) | +20,848 | $403.7K | EDGAR |
| 2016-03-22 | Mirati Therapeutics, Inc. (MRTX) Delisted | Buy (P) | +1,166 | $22.6K | EDGAR |
| 2016-03-17 | Mirati Therapeutics, Inc. (MRTX) Delisted | Other (J) | +375,298 | $0 | EDGAR |
Notice (144 / 144/A): Form 144 is a notice of intent to sell restricted/control stock under Rule 144, filed before the sale; 144/A is an amendment. Many notices are pre-scheduled under Rule 10b5-1 plans. A Form 4 with code S typically follows within a few days when the planned sale executes; missing follow-up Form 4s suggest the notice was cancelled or modified.